On the other hand, pooling data showed use of DPP-4 inhibitors favored lower risk of myocardial infarction events as compared to use of sulfonylureas (OR: 0.41, 95% CrI: 0.24–0.71), and the result of node-splitting analysis did not found any inconsistency between the direct and indirect comparisons (Table 2; p-value = 0.53125). This evidence concerns the gene DPP4 and myocardial infarction.